Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PORT: Peripheral vs Central Melflufen in RRMM
NCT04412707Phase 2Terminated
- Sponsor
- Oncopeptides AB
- Start
- Aug 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 5
01
Overview
A Phase 2 trial of melphalan flufenamide in multiple myeloma (MM), sponsored by Oncopeptides AB. Started Aug 2020; status: terminated.
02
Drugs
melphalan flufenamide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04412707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04412707.